

# COVID-19 WEEKLY BULLETIN



## Global Epidemiological update

The COVID-19 weekly Epidemiological update from WHO shows a decline of cases and deaths across the globe for the 6th Consecutive week. 112 million people have been infected across the globe with more than 2.5 million deaths. Only the regions of South East Asia and Eastern Mediterranean region showed an increase in cases as India reported a 10% in cases over the past week. USA, Brazil, France, Russia and India reported the maximum cases in the week.

### Total Vaccinated with Covid-19 Vaccine

World 231 million

India 13.4 million

Nagaland 35,262

as on 26 February 2021

## COVID-19 CASES SURGE IN INDIA

India is seeing a surge in cases for the past week from states like Maharashtra, Kerala, Gujarat, Punjab, Madhya Pradesh and Chhattisgarh. ICMR has clarified that there is no linkage between surge in COVID-19 cases with the mutant strains N440K and E484Q detected in several states of India since last year. Complacency, opening of local transport and institutions, and deviation from COVID-19 appropriate behaviors are responsible for the surge in cases as COVID-19 comes in waves after waves. Several states have made negative RT-PCR COVID-19 test mandatory for people coming from the affected states.

### UPDATE on SARS COV 2 VARIANTS OF CONCERN

SARS COV 2 VARIANTS of Concern (WHO Criteria):

- Increase in transmissibility or detrimental change in COVID-19 epidemiology
- Increase in virulence or change in clinical disease presentation; or
- Decrease in effectiveness of public health and social measures or available diagnostics, vaccines, therapeutics

Nextstrain clade	20I/501Y.V1	20H/501Y.V2†	20J/501Y.V3
<b>Pango lineage</b>	B.1.1.7	B.1.351	B.1.1.28.1
<b>First detected by</b>	United Kingdom	South Africa	Brazil / Japan
<b>First appearance</b>	20 September 2020	Early August 2020	December 2020
<b>Transmissibility</b>	Increased (36%-75%), increased secondary attack rate (10% to 13%)	Increased [1.50 (95% CI 1.20-2.13) times more transmissible than previously circulating variants	Suggested to be increased
<b>Severity</b>	Possible increased severity & mortality.	No impact reported to date, no significant change in-hospital mortality	Under investigation, no impact reported to date.
<b>Potential impacts on vaccines*</b>	No significant impact on Moderna, Pfizer BioNTech, & Oxford AstraZeneca vaccines 13-16	Moderna & Pfizer-BioN-Tech: Reduction in the neutralizing activity, but impact on protection against disease not known.	Under investigation
<b>Countries reporting cases</b>	101	51	29

WHO has released guideline to countries for surveillance of variants by increasing testing and genomic sequencing, and increasing efforts to stop transmissions through COVID-19 appropriate behaviors and Vaccines.

## India to start vaccination of age appropriate groups from first week of March 2021

From MARCH 2021, the following age groups will be vaccinated across the country;

1. All citizens above 60 years and above as on 1st January 2022
2. All citizens aged 45-59 years of age as on 1st January 2022 with the following comorbidities or diseases subject to certification by a Registered Medical Practitioner:

Heart Failure with hospital admission in past one year

Post Cardiac Transplant/Left Ventricular Assist Device (LVAD)

Significant Left ventricular systolic dysfunction (LVEF <40%)

Moderate or Severe Valvular Heart Disease

Congenital heart disease with severe PAH or Idiopathic PAH

Coronary Artery Disease with past CABG/PTCA/MI

AND Hypertension/Diabetes on treatment

Angina AND Hypertension/Diabetes on treatment

CT/MRI documented stroke AND Hypertension/Diabetes on treatment

Pulmonary artery hypertension AND Hypertension/Diabetes on treatment

Diabetes (> 10 years OR with complications) AND Hypertension on treatment

Kidney/ Liver/ Hematopoietic stem cell transplant: Recipient/On wait-list

End Stage Kidney Disease on hemodialysis/ CAPD

Current prolonged use of oral corticosteroids/ immunosuppressant medications

Decompensated cirrhosis

Severe respiratory disease with hospitalizations in last two years/FEV1 <50%

Lymphoma/ Leukaemia/ Myeloma

Diagnosis of any solid cancer on or after 1st July 2020 OR currently on any cancer therapy

Sickle Cell Disease/ Bone marrow failure/ Aplastic Anemia/ Thalassemia Major

Primary Immunodeficiency Diseases/ HIV infection

Persons with disabilities due to Intellectual disabilities/ Muscular Dystrophy/ Acid attack with involvement of respiratory system/ Persons with disabilities having high support needs/ Multiple disabilities including deaf-blindness

3. Left out Healthcare and frontline workers will continue to get the vaccine.

### Key Points on vaccination of Age-Appropriate Groups;

1. The vaccination will be done at identified government (free) and private (chargeable) health facilities.
2. Beneficiaries will have to be registered in COWIN 2.0 portal (Advance self-registration or onsite registration) and Photo ID will be compulsory.
3. The three categories are prioritized as they are at the highest risk of infection, severe disease or death by COVID-19 disease.

## COVID-19 VACCINATION REDUCES SEVERE DISEASE SIGNIFICANTLY

Israel was one of the first countries to launch a Nationwide COVID-19 vaccination campaign focusing on the high-risk groups (elderly). The Morbidity and Mortality Report (CDC, USA) reports a significant reduction in severe disease among the elderly who were vaccinated. By Feb 2021, Israel's second dose coverage in the 70 plus age group was 84% and less than 10% in the below 50 age group. After the vaccination campaign, the ratio of COVID-19 patients requiring mechanical ventilation in 70 plus age group to those below 50 years declined by 67%.

Covid 19 Cases	Confirmed cases	Deaths	Death Rate
World	11,26,49,371	25,01,229	2.22%
India	1,10,63,491	1,56,825	1.42%
Nagaland	12,198	81	0.66%

As on 26 February 2021

State	Total Cases	No of Deaths	Death Rate
Assam	2,17,344	1091	0.50 %
Tripura	33,366	391	1.17 %
Manipur	29,225	373	1.28 %
Meghalaya	13,946	148	1.06 %
Sikkim	6,126	135	2.20 %
Nagaland	12,191	81	0.66 %
Arunachal Pradesh	16,836	56	0.33 %
Mizoram	4,405	10	0.23 %
Total	3,33,439	2285	0.69 %

In the past week:

World: 26,52,083 cases and 66,084 deaths.

India: 1,00,097 cases and 714 deaths.


Nagaland: 7 cases and 0 deaths.

**COVID-19 VACCINATION IN NAGALAND FOR HEALTHCARE & FRONTLINE WORKERS**


District	Frontline Workers	Health Care Workers		Total dose administered
		1 <sup>st</sup> Dose	2 <sup>nd</sup> Dose	
Dimapur	6629	2344	1435	10408
Kohima	3943	2002	983	6928
Mokokchung	1271	1260	675	3206
Mon	1577	742	355	2674
Zunheboto	1400	737	398	2535
Phek	1173	564	434	2171
Wokha	1119	684	317	2120
Peren	534	745	427	1706
Tuensang	857	463	271	1591
Longleng	624	304	93	1021
Kiphire	479	314	109	902
<b>State</b>	<b>19606</b>	<b>10159</b>	<b>5497</b>	<b>35,262</b>

**35,262 doses administered across Nagaland**

**TOTAL BENEFICIARIES**



## MONTHLY COVID-19 TESTS BY RT PCR, TRUENAT AND RAT (%)



### DISTRICT WISE TESTING IN THE PAST WEEK

District	Total tests	% of RT PCR/ Truenat
Dimapur	584	1 %
Kiphire	19	100 %
Kohima	196	68 %
Longleng	22	0 %
Mokokchung	81	16 %
Mon	113	5 %
Peren	9	22 %
Phek	12	25 %
Tuensang	58	0 %
wokha	10	50 %
Zunheboto	24	0 %
<b>State</b>	<b>1,176</b>	<b>30%</b>


### 7 REASONS WHY YOU SHOULD GET VACCINATED!

1. The Vaccine will prevent you from getting infected by the SARS-CoV-2 Virus.
2. Even if you get infected, the Vaccine will prevent severe disease, hospitalization or death.
3. The vaccine is very safe. Only mild side effects like fever, pain at injection site, headache, malaise is expected after vaccination.
4. No long-term side effects are expected since the vaccines used are old and tried tested technology used in other vaccines.
5. The vaccine will shorten the duration of the Pandemic and help us get back safely to our normal lives.
6. Getting yourself vaccinated will protect people around you and vaccination is a social responsibility.
7. The emergence of SARS COV 2 variants adds to the urgency of vaccination.


# CONFIRMED CASES (weekly data)

7 confirmed cases this week

## WEEKLY DATA OF CONFIRMED CASES AND DEATHS



## WEEKLY DATA ON SAMPLE TESTING & SAMPLE POSITIVITY RATE



### CONFIRMED CASES THIS WEEK

Age Group	Cases
Traced Contacts/Self-test	2
Travelers	2
Armed forces/ Security	3
Frontline workers	0
<b>TOTAL</b>	<b>7</b>

**84%** of total tests were done by RAT in the past week


Test Type	No of tests	%
RT PCR	74710	57
TRUENAT	37344	29
RAT	17972	14
<b>TOTAL</b>	<b>1,30,026</b>	<b>100%</b>

# COVID DEATHS

- Total Deaths: 81
- Median Age: 55 yrs
- Range: 24 - 90 yrs
- Gender: Males 73%
- Deaths with comorbidities: 84%


All COVID-19 deaths are certified by the state death committee as per ICMR and WHO ICD 10 guideline.

## DEATHS (ASSOCIATED COMORBIDITIES)



**Multiple comorbidities are associated with a single patient.**

## COVID-19 DEATHS BY AGE GROUP



**58% deaths are below 60 years.**

**Most common affected age group is 40-49 and 30-39-year age groups.**


## Most common comorbidities: Diabetes & Hypertension

Going back to our normal lives safely will need discipline and maintenance of COVID-19 appropriate behaviors like wearing mask, washing hands frequently and maintaining physical distancing along with vaccination of the population till and when a certain level of Immunity is achieved in the population.

### VACCINES AND COVID-19 APPROPRIATE BEHAVIOURS ARE OUR SAFEST ROUTE BACK TO THE NORMAL LIVES!

Isolate, get yourself tested and get help if you have any covid-19 like symptoms or if you come in contact with a positive case. Let us protect ourselves and the vulnerable people in the community by being more careful and responsible. Let us all adopt COVID-19 appropriate behaviours during this crucial time.

## TESTING, POSITIVITY, RECOVERY AND MORTALITY RATES




DATA AS ON 26 FEBRUARY 2021

## CATEGORIZATION OF TOTAL CONFIRMED CASES

Total confirmed cases till date: 12,198

### CLINICAL PRESENTATION OF SYMPTOMATIC CASES



**fever  
cough  
breathlessness**

most common presenting  
feature among  
symptomatic cases

**Anyone with such reported symptoms should self-isolate and seek medical help as necessary.**

### DESCRIPTIVE EPIDEMIOLOGY

Characteristics	Number/Percentage
Median Age of Positive Cases	33 years
Range (Age) of Positive Cases	1 month - 98 years
Cases with comorbidity	1%
Symptomatic Cases	5%

# CONTACT TRACING

A total of 35,222 contacts have been traced by surveillance teams across all districts.

Contact tracing remains as one of the crucial pillars of COVID-19 control. Self-test implies category of people who have been tested without any history of contact either for travel, symptomatic, work place related or for medical treatment in a hospital

## DISTRIBUTION OF POSITIVE TRACED CONTACTS BY AGE-GROUP & OCCUPATION

Age Group	Cases	Percentage
0.1-10	338	7
11 -20	651	13
21-30	1307	26
31-40	1271	25
41-50	771	15
51-60	457	9
61-98	301	6
<b>TOTAL</b>	<b>5,096</b>	<b>100%</b>

Gender	Cases	Percentage
Female	2017	40
Male	3079	60
<b>TOTAL</b>	<b>5,096</b>	<b>100%</b>

Occupation/Place of infection	Cases	Percentage
Household contacts	1457	29
Government employees	1207	24
Students	958	19
Self employed	797	16
Unemployed	199	4
Prison contacts	138	3
Teachers	73	1
Migrant workers	69	1
Convent contacts	62	1
Church contacts	34	0.7
Bank Staff	28	0.6
Bakery/Restaurant employee	24	0.5
Shelter home	18	0.4
Taxi Drivers	18	0.4
Media persons	7	0.1
NGO staff	7	0.1
Symptomatic/ Pre-op/Travel	826	16
<b>TOTAL</b>	<b>5,096</b>	<b>100%</b>




## DISTRICT DISTRIBUTION OF ACTIVE CASES AND SAMPLING

District	Total Cases	Active Cases	Deaths	Samples Tested	Tests per thousand population	Positivity Rate
Kohima	3879	8	21	38092	137	10.2 %
Dimapur	6478	1	52	52131	133	12.4 %
Kiphire	41	0	1	1226	16	3.3 %
Longleng	19	0	0	1235	24	1.5 %
Mokokchung	193	0	3	5272	26	3.7 %
Mon	605	0	2	13298	51	4.5 %
Peren	507	0	0	5987	61	8.5 %
Phek	47	0	0	3060	18	1.5 %
Tuensang	248	0	1	5881	29	4.2 %
Wokha	39	0	1	1635	10	2.4 %
Zunheboto	142	0	0	2209	15	6.4 %
Total	12198	9	81	130026	64	9.4 %

# NAGALAND

## COVID-19 ACTIVE CASES

AS ON 26 FEBRUARY 2021



\*For data reporting, Noklak is covered under Tuensang district as there is no separate surveillance unit yet for the district.

# PROTECT AGAINST COVID-19



**GET VACCINATED**




**WEAR A MASK**



**MAINTAIN 6 FT.DISTANCE  
& AVOID CROWDS**




**WASH HANDS  
FREQUENTLY**

 [www.nagahealth.nagaland.gov.in](http://www.nagahealth.nagaland.gov.in)

 @MyGovNagaland

 [www.covid19.nagaland.gov.in](http://www.covid19.nagaland.gov.in)

 @HealthNagaland

 [www.nsdma.nagaland.gov.in](http://www.nsdma.nagaland.gov.in)

 Coronaga



**DR.NYANTHUNG KIKON**  
State Nodal Officer  
IDSP, H&FW  
Nagaland